Observation on the Influence of Valsartan Combined with Bailing Capsules on Urinary Albumin Excretion Rate in Early Stage of Type 2 Diabetic Nephropathy
- VernacularTitle:缬沙坦联合百令胶囊对早期糖尿病肾病患者尿白蛋白排泄率的影响观察
- Author:
Li WU
;
Dajun YAN
;
Shijuan JING
;
Jianmin YU
;
Jilu GENG
- Publication Type:Journal Article
- Keywords:
Valsartan;
Bailing capsule;
Diabetice nephropathy;
Urine albumin excretion rate
- From:
China Pharmacist
2014;(9):1532-1533,1534
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the influence of valsartan combined with Bailing capsules on urinary albumin excretion rate in early stage of type 2 diabetic nephropathy ( DN) , and explore its protection in early DN. Methods:Sixty patients with early DN were randomly divided into two groups. On the basis of diet control and blood glucose regulation, the control group (n=30) was given valsartan 160 mg, qd, while the prevention group (n=30) was treated by valsartan (160 mg·d-1) combined with Bailing capsules (2. 0g, po, tid), and the treatment course was 12 weeks. The urinary albumin excretion rate ( UAER) , mean arterial blood pressure ( MAP) , serum creat-inine ( Scr) and hemoglobin A1c ( HbA1c) were measured and compared before and after the treatment in the two groups. Results:UAER in the two groups was significantly reduced after the treatment compared with that before the treatment (P<0. 01), and that in the prevention group was obviously lower than that in the control group (P<0. 01). MAP in the two groups was significantly decreased after the treatment as well (P<0. 01), while there was no significant difference between the two groups. Scr and Hb Alc in the two groups showed no significant changes before and after the treatment (P>0. 05). Conclusion:Valsartan combined with Bailing capsules shows certain effects in the treatment of early stage of type 2 diabetic nephropathy by decreasing the urinary albumin excretion.
